PTC Therapeutics clinical trials we track

Check company identity source

Phase 3 7 trials

Phase 2 / 3 4 trials

Phase 2 5 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants With Adverse Events Time frame: Baseline up to end of study (up to approximately 8 years) Measure: Number of Participants With Laboratory Parameters Abnormalities Description: Laboratory parameters include hematological, serum biochemistry, adrenal laboratories, and urine data. Time frame: Baseline up to end of study (up to approximately 8 years) Measure: Number of Participants With Abnormal Physical Findings Description: Physical findings include weight, physical examination data, systolic and diastolic blood pressure, radial pulse rate, and body temperature. Time frame: Baseline up to end of study (up to approximately 8 years). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. Time frame: Baseline up to end of study (up to approximately 15 years).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 270 participants (planned). After: 265 participants (actual).

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 200 participants (planned). After: 247 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 Jun 2026. After: 21 Jul 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score at Week 72. After: Measure: Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set Measure: Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days. After: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Slope of Change in 6-Minute Walk Distance (6MWD) Over 72 Weeks. After: Measure: DB Period: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 72 - Modified Intention-to-treat (mITT) Population Measure: DB Period: Change From Baseline in 6MWD at Week 72 - Intent-to-Treat (ITT) Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - mITT Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - ITT Population.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants With Adverse Events (AEs). After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs).

Check registry source